These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

813 related items for PubMed ID: 10792853

  • 1. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE, Bonnelye E.
    Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
    [Abstract] [Full Text] [Related]

  • 2. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
    Aubin JE, Bonnelye E.
    Osteoporos Int; 2000 Mar; 11(11):905-13. PubMed ID: 11193242
    [Abstract] [Full Text] [Related]

  • 3. [New paradigms in the regulation of bone metabolism].
    Rosa-Rañal M, de la Cruz DA, Lorena-Rubio Y, Larrea F.
    Rev Invest Clin; 2001 Mar; 53(4):362-9. PubMed ID: 11599485
    [Abstract] [Full Text] [Related]

  • 4. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.
    Takahashi N, Udagawa N, Suda T.
    Biochem Biophys Res Commun; 1999 Mar 24; 256(3):449-55. PubMed ID: 10080918
    [Abstract] [Full Text] [Related]

  • 5. [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].
    Mochizuki S, Kiyokawa A, Nagayama Y.
    Clin Calcium; 2005 Jan 24; 15(1):35-42. PubMed ID: 15632471
    [Abstract] [Full Text] [Related]

  • 6. Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Ann N Y Acad Sci; 2006 Apr 24; 1068():225-33. PubMed ID: 16831922
    [Abstract] [Full Text] [Related]

  • 7. Osteoprotegerin and inflammation.
    Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC.
    Eur Cytokine Netw; 2002 Apr 24; 13(2):144-53. PubMed ID: 12101070
    [Abstract] [Full Text] [Related]

  • 8. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis.
    Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S.
    Arthritis Rheum; 2000 Feb 24; 43(2):259-69. PubMed ID: 10693864
    [Abstract] [Full Text] [Related]

  • 9. [Osteoclast function is regulated by neighbouring osteoblasts. Osteoprotegerin, RAND and RANK ligand constitute a unique regulatory system for bone resorption with important pathophysiological and therapeutic aspects].
    Ueland T, Bollerslev J, Mosekilde L.
    Ugeskr Laeger; 2002 Jul 01; 164(27):3526-30. PubMed ID: 12116680
    [Abstract] [Full Text] [Related]

  • 10. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
    Giuliani N, Colla S, Rizzoli V.
    Exp Hematol; 2004 Aug 01; 32(8):685-91. PubMed ID: 15308315
    [Abstract] [Full Text] [Related]

  • 11. Dual modulation of osteoclast differentiation by lipopolysaccharide.
    Zou W, Bar-Shavit Z.
    J Bone Miner Res; 2002 Jul 01; 17(7):1211-8. PubMed ID: 12096834
    [Abstract] [Full Text] [Related]

  • 12. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF, Lie A, Ransjö M.
    J Cell Biochem; 2006 Oct 01; 99(2):528-37. PubMed ID: 16639710
    [Abstract] [Full Text] [Related]

  • 13. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
    Kanatani M, Sugimoto T, Kano J, Kanzawa M, Chihara K.
    J Cell Physiol; 2003 Jul 01; 196(1):180-9. PubMed ID: 12767054
    [Abstract] [Full Text] [Related]

  • 14. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
    Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E.
    Bone; 2005 Jan 01; 36(1):159-72. PubMed ID: 15664014
    [Abstract] [Full Text] [Related]

  • 15. [The molecular mechanism of osteoclastic bone resorption and inhibitory drugs for bone resorption].
    Yamamoto Y, Noguchi T, Udagawa N.
    Clin Calcium; 2005 Jul 01; 15(7):11-6. PubMed ID: 15995290
    [Abstract] [Full Text] [Related]

  • 16. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
    Koh JM, Lee YS, Byun CH, Chang EJ, Kim H, Kim YH, Kim HH, Kim GS.
    J Endocrinol; 2005 Jun 01; 185(3):401-13. PubMed ID: 15930166
    [Abstract] [Full Text] [Related]

  • 17. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
    Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H.
    Biochem Biophys Res Commun; 2000 Sep 07; 275(3):768-75. PubMed ID: 10973797
    [Abstract] [Full Text] [Related]

  • 18. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D.
    Cytokine Growth Factor Rev; 2004 Dec 07; 15(6):457-75. PubMed ID: 15561602
    [Abstract] [Full Text] [Related]

  • 19. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH, Kirschenbaum A, Yao S, Levine AC.
    Endocrinology; 2005 Apr 07; 146(4):1991-8. PubMed ID: 15618359
    [Abstract] [Full Text] [Related]

  • 20. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM, Pearse RN.
    Cancer; 2003 Feb 01; 97(3 Suppl):802-12. PubMed ID: 12548579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.